Lisa E. Davis

3.6k total citations · 1 hit paper
43 papers, 2.4k citations indexed

About

Lisa E. Davis is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa E. Davis has authored 43 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa E. Davis's work include Multiple Myeloma Research and Treatments (7 papers), Autophagy in Disease and Therapy (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lisa E. Davis is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Autophagy in Disease and Therapy (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lisa E. Davis collaborates with scholars based in United States, South Africa and India. Lisa E. Davis's co-authors include Ravi K. Amaravadi, Shengfu Piao, Daniel F. Heitjan, Yunyoung C Chang, Laura Pontiggia, Quentin McAfee, Peter J. O’Dwyer, Edward C. Li, Andrea B. Troxel and Reshma Rangwala and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Lisa E. Davis

41 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

2014 409 citations Myrna R. Rosenfeld, Xiaobu Ye et al. Autophagy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa E. Davis United States	20	1.3k	1.2k	383	360	334	43	2.4k
Yan Cheng China	32	932 0.7×	1.6k 1.3×	437 1.1×	67 0.2×	813 2.4×	104	3.2k
Wolfgang E. Thasler Germany	35	932 0.7×	1.6k 1.3×	994 2.6×	41 0.1×	339 1.0×	131	4.3k
Davide Sartini Italy	31	332 0.3×	1.3k 1.1×	650 1.7×	90 0.3×	243 0.7×	87	2.5k
Huihui Xu China	31	407 0.3×	1.5k 1.3×	245 0.6×	45 0.1×	263 0.8×	92	2.4k
Yunfeng Fu China	27	318 0.2×	1.2k 1.0×	281 0.7×	53 0.1×	774 2.3×	102	2.2k
Jianjun Zhang China	25	492 0.4×	796 0.7×	292 0.8×	40 0.1×	460 1.4×	126	2.2k
Dahn L. Clemens United States	27	976 0.7×	733 0.6×	344 0.9×	23 0.1×	105 0.3×	73	2.4k
Emeric Limagne France	32	215 0.2×	1.5k 1.2×	1.2k 3.2×	104 0.3×	503 1.5×	61	3.5k
Usha R. Pendurthi United States	36	235 0.2×	1.2k 1.0×	290 0.8×	44 0.1×	501 1.5×	131	4.1k
Shuichi Seki Japan	28	1.4k 1.1×	942 0.8×	317 0.8×	17 0.0×	214 0.6×	129	3.4k

Countries citing papers authored by Lisa E. Davis

Since Specialization

Citations

This map shows the geographic impact of Lisa E. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa E. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa E. Davis more than expected).

Fields of papers citing papers by Lisa E. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa E. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa E. Davis. The network helps show where Lisa E. Davis may publish in the future.

Co-authorship network of co-authors of Lisa E. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa E. Davis. A scholar is included among the top collaborators of Lisa E. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa E. Davis. Lisa E. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davis, Lisa E., et al.. (2024). Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. Cancer Chemotherapy and Pharmacology. 94(3). 361–372. 1 indexed citations

Nix, David E., et al.. (2021). The relationship of vancomycin 24-hour AUC and trough concentration. American Journal of Health-System Pharmacy. 79(7). 534–539. 10 indexed citations

Haas, Naomi B., Leonard J. Appleman, Mark N. Stein, et al.. (2019). Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research. 25(7). 2080–2087. 112 indexed citations

Mollon, Lea, Elizabeth J. Anderson, Terri Warholak, et al.. (2019). A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer. Clinical Breast Cancer. 20(3). e232–e243. 32 indexed citations

Wetzel, Christine, et al.. (2019). A Quality Improvement Project to Improve the Use of Mother's Own Milk (MOM) With Precision Oropharyngeal Therapy. Advances in Neonatal Care. 20(2). E19–E30. 5 indexed citations

Garland, Linda L., José Guillen-Rodriguez, Chiu‐Hsieh Hsu, et al.. (2019). Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial. Cancer Prevention Research. 12(11). 809–820. 7 indexed citations

Davis, Lisa E., et al.. (2019). PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. Cancer Immunology Research. 7(9). 1396–1400. 20 indexed citations

Mollon, Lea, Elizabeth J. Anderson, Lisa E. Davis, et al.. (2018). Abstract 1207: A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2- metastatic breast cancer. Cancer Research. 78(13_Supplement). 1207–1207. 26 indexed citations

Park, So‐Young, Lisa E. Davis, Paul Hsu, Daniel O. Persky, & Daruka Mahadevan. (2017). Phase II/1b Trial of Ibrutinib Plus Prednisone and Rituximab Induction Followed By Venetoclax Plus Ibrutinib Maintenance in Newly Diagnosed High-Risk Chronic Lymphocytic Leukemia. Blood. 130. 5351–5351. 1 indexed citations

10.

Rangwala, Reshma, Robert D. Leone, Yunyoung C Chang, et al.. (2014). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10(8). 1369–1379. 294 indexed citations

11.

Mahalingam, Devalingam, Monica Mita, John Sarantopoulos, et al.. (2014). Combined autophagy and HDAC inhibition. Autophagy. 10(8). 1403–1414. 241 indexed citations

12.

Rosenfeld, Myrna R., Xiaobu Ye, Jeffrey G. Supko, et al.. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 10(8). 1359–1368. 409 indexed citations breakdown →

13.

Vogl, Dan T., Edward A. Stadtmauer, Daniel F. Heitjan, et al.. (2014). Combined autophagy and proteasome inhibition. Autophagy. 10(8). 1380–1390. 314 indexed citations

14.

Davis, Lisa E., et al.. (2013). Communicating Doses of Pediatric Liquid Medicines to Parents/Caregivers: A Comparison of Written Dosing Directions on Prescriptions with Labels Applied by Dispensed Pharmacy. The Journal of Pediatrics. 164(3). 596–601.e1. 12 indexed citations

15.

Vogl, Dan T., Eric T. Stoopler, Lisa E. Davis, et al.. (2010). Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma. Blood. 116(21). 1349–1349. 4 indexed citations

16.

Zuppa, Athena F., John Mondick, Lisa E. Davis, & David Cohen. (2009). Population Pharmacokinetics of Ketorolac in Neonates and Young Infants. American Journal of Therapeutics. 16(2). 143–146. 21 indexed citations

17.

Davis, Lisa E., Welma Stonehouse, Du Toit Loots, et al.. (2007). The effects of high walnut and cashew nut diets on the antioxidant status of subjects with metabolic syndrome. European Journal of Nutrition. 46(3). 155–164. 98 indexed citations

18.

Veronese, M L, Weijing Sun, Bruce J. Giantonio, et al.. (2005). A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. British Journal of Cancer. 92(10). 1846–1849. 42 indexed citations

19.

Li, Edward C. & Lisa E. Davis. (2003). Zoledronic acid: A new parenteral bisphosphonate. Clinical Therapeutics. 25(11). 2669–2708. 92 indexed citations

20.

Marro, Peter J., Stephen Baumgart, Maria Delivoria‐Papadopoulos, et al.. (1997). Purine Metabolism and Inhibition of Xanthine Oxidase in Severely Hypoxic Neonates Going onto Extracorporeal Membrane Oxygenation1. Pediatric Research. 41(4). 513–520. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact